The demo attained both of those its Major endpoints, with semaglutide 2.four mg demonstrating statistically considerable and top-quality advancements in liver fibrosis with no worsening of steatohepatitis, in addition to resolution of steatohepatitis without any worsening of liver fibrosis in those with MASH when compared with placebo.1Your Mounjar